We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

56 hedge funds and large institutions have $68.4M invested in VYNE Therapeutics in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

21% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 14

8% more funds holding

Funds holding: 52 → 56 (+4)

0.01% more ownership

Funds ownership: 0.99% → 0.99% (+0.01%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

57% less capital invested

Capital invested by funds: $161M → $68.4M (-$92.3M)

Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
15
Increased
17
Reduced
14
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$5.6M
2
First Manhattan
First Manhattan
New York
+$2.35M
3
DCM
DAFNA Capital Management
California
+$1.42M
4
AIM
Alambic Investment Management
California
+$1.07M
5
JP Morgan Chase
JP Morgan Chase
New York
+$736K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$4.66M
2
RSCM
Rock Springs Capital Management
Maryland
-$3.25M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$2.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.87M
5
NHAS
Novo Holdings A/S
Denmark
-$1.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$148K +$41.2K +92 +23%
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$147K +$223K +498 New
Deutsche Bank
28
Deutsche Bank
Germany
$121K -$65.4K -146 -26%
TD Asset Management
29
TD Asset Management
Ontario, Canada
$116K – – –
Renaissance Technologies
30
Renaissance Technologies
New York
$81K -$72.1K -161 -37%
MWNA
31
Marshall Wace North America
New York
$80K +$120K +269 New
Ameriprise
32
Ameriprise
Minnesota
$74K +$111K +249 New
Two Sigma Advisers
33
Two Sigma Advisers
New York
$72K +$8.95K +20 +9%
PPA
34
Parametric Portfolio Associates
Washington
$67K +$101K +226 New
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$66K +$8.95K +20 +10%
Wells Fargo
36
Wells Fargo
California
$64K +$88.2K +197 +938%
Squarepoint
37
Squarepoint
New York
$59K -$83.7K -187 -49%
Citadel Advisors
38
Citadel Advisors
Florida
$57K +$86.4K +193 New
TA
39
Teachers Advisors
New York
$51K – – –
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$48K +$72.1K +161 New
TRCT
41
Tower Research Capital (TRC)
New York
$44K +$66.3K +148 New
UBS Group
42
UBS Group
Switzerland
$36K +$53.7K +120 New
AIG
43
American International Group
New York
$26K -$448 -1 -1%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$14K – – –
Citigroup
45
Citigroup
New York
$10K -$448 -1 -3%
Legal & General Group
46
Legal & General Group
United Kingdom
$5K – – –
MAM
47
Meeder Asset Management
Ohio
$5K +$1.79K +4 +33%
Macquarie Group
48
Macquarie Group
Australia
$5K +$8.06K +18 New
Federated Hermes
49
Federated Hermes
Pennsylvania
$3K +$4.03K +9 New
AIP
50
Ameritas Investment Partners
Nebraska
$2K – – –
1
2
3

VYNE Hedge Fund Activity: Q4 2018 in Review

56 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2018, worth a combined $68.4M — down 57% from $161M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new VYNE positions and 11 closed out — a net gain of 4 holders — while 17 added to existing stakes and 14 trimmed.

The largest buyer was Great Point Partners, adding an estimated $5.6M. The largest seller was OrbiMed, exiting entirely with an estimated $4.66M sold.

  • 56 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2018, up from 52 in Q3 2018.
  • Funds reported $68.4M of VYNE Therapeutics stock for Q4 2018, down 57% quarter-over-quarter.
  • 15 funds opened new VYNE Therapeutics positions in Q4 2018 and 11 closed out, a net change of +4 holders.
  • The largest VYNE Therapeutics buyer in Q4 2018 was Great Point Partners, an estimated $5.6M added.
  • The largest VYNE Therapeutics seller in Q4 2018 was OrbiMed, an estimated $4.66M sold.

Based on aggregated 13F filings for Q4 2018.